The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease

Background: Parkinson's disease (PD) is an incurable, progressive neurological condition, with symptoms impacting movement, walking, and posture that eventually become severely disabling. Advanced PD (aPD) has a significant impact on quality-of-life (QoL) for patients and their caregivers/families. Levodopa/carbidopa intestinal gel (LCIG) is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyper-/dyskinesia when available combinations of therapy have not given satisfactory results.Aims: To determine the cost-effectiveness of LCIG vs standard of care (SoC) for the treatment of aPD patients.Methods: A Markov model was used to evaluate LCIG vs SoC in a hypothetical cohort of 100 aPD patients with severe motor fluctuations from an Irish healthcare perspective. Model health states were defined by Hoehn & Yahr (H&Y) scalecombined with amount of time in OFF-timeand death. SoC comprised of standard oral therapysubcutaneous apomorphine infusion and standard follow-up visits. Clinical efficacy, utilities, and transition probabilities were derived from published studies. Resource use was estimated from individual patient-level data from Adelphi 2012 UK dataset, using Irish costs, where possible. Time horizon was 20 years. Costs and outcomes were discounted at 4%. Both one-way and probabilistic sensitivity analyses were conducted.Results: The incremental cost-effectiveness ratio for LCIG vs SOC was Euro26,944/quality adjusted life year (QALY) (total costs and QALYs for LCIG vs SoC: Euro537,687 vs Euro514,037 and 4.37 vs 3.49, respectively). LCIG is cost-effective at a payer threshold of Euro45,000. The model was most sensitive to health state costs.Conclusion: LCIG is a cost-effective treatment option compared with SoC in patients with aPD.